CN110632205A - Method for detecting salbutamol sulfate solution related substances for inhalation - Google Patents
Method for detecting salbutamol sulfate solution related substances for inhalation Download PDFInfo
- Publication number
- CN110632205A CN110632205A CN201910950434.0A CN201910950434A CN110632205A CN 110632205 A CN110632205 A CN 110632205A CN 201910950434 A CN201910950434 A CN 201910950434A CN 110632205 A CN110632205 A CN 110632205A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- solution
- vol
- detection
- phosphate buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000000126 substance Substances 0.000 title claims abstract description 12
- 238000001514 detection method Methods 0.000 claims abstract description 47
- 239000012535 impurity Substances 0.000 claims abstract description 47
- 239000000243 solution Substances 0.000 claims abstract description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000010828 elution Methods 0.000 claims abstract description 16
- 229960002052 salbutamol Drugs 0.000 claims abstract description 15
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract description 11
- 239000011259 mixed solution Substances 0.000 claims abstract description 9
- 238000004811 liquid chromatography Methods 0.000 claims abstract description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 3
- 239000012071 phase Substances 0.000 claims description 47
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 6
- 229910001413 alkali metal ion Inorganic materials 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 229910001414 potassium ion Inorganic materials 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- 239000012085 test solution Substances 0.000 claims description 4
- WHJAFZHZZCVHJI-UHFFFAOYSA-N 2-(tert-butylamino)-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanone Chemical compound CC(C)(C)NCC(=O)C1=CC=C(O)C(CO)=C1 WHJAFZHZZCVHJI-UHFFFAOYSA-N 0.000 claims description 3
- 239000012074 organic phase Substances 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical group OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 229940057282 albuterol sulfate Drugs 0.000 claims 2
- -1 albuterol ketone Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 6
- 229940088679 drug related substance Drugs 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000037874 Asthma exacerbation Diseases 0.000 description 1
- 101000777138 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 42 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100031310 Ubiquitin carboxyl-terminal hydrolase 42 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a method for detecting related substances of salbutamol sulfate solution for inhalation, which adopts a high performance liquid chromatography method to carry out qualitative or/and quantitative detection on related substances of salbutamol sulfate solution for inhalation, wherein the detection conditions of the liquid chromatography comprise: the chromatographic column is a C8 chromatographic column, and the mobile phase comprises a mobile phase A and a mobile phase B, wherein the mobile phase A is a phosphate buffer solution; the mobile phase B is acetonitrile: the volume ratio of methanol is (40-65): (60-35) of a mixed solution; the mobile phase adopts a gradient elution method. The method can effectively detect the main drug and other related impurities in the salbutamol sulfate solution for inhalation, has specificity and stability indicating capability, and can detect new impurity 5-hydroxy salbutamol.
Description
Technical Field
The invention relates to the field of detection methods, in particular to a detection method of substances related to salbutamol sulfate solution for inhalation.
Background
Salbutamol sulfate is a selective beta2Adrenergic receptor agonists, bronchodilators with rapid onset (within 5 minutes), short-acting (4 to 6 hours) on reversible airway obstruction. At therapeutic doses, act on beta located on bronchial smooth muscle2The adrenergic receptor, because of its rapid onset of action, is particularly well suited for use in the treatment and prevention of asthma exacerbations.
The aerosol therapeutic medicine can reach the affected part directly, so the aerosol inhalation is widely applied in the department of respiration, and the aerosol inhalation is mostly adopted in the using mode of salbutamol sulfate at present, so that the patient mostly uses the salbutamol sulfate solution preparation for inhalation, compared with other therapeutic modes, the aerosol inhalation therapeutic medicine is more convenient to use and faster in effect, and the market demand of the salbutamol sulfate solution for inhalation is growing quietly.
However, in the pharmacopoeias of many countries, such as EP9.8, USP42, and ChP2015, there is no record of salbutamol sulfate for inhalation; in BP2019, "salbutamol sulfate solution for inhalation" was recorded, but the impurities were less detectable.
Therefore, the quality control method of salbutamol sulfate solution for inhalation needs to be further developed, improved and perfected.
Disclosure of Invention
The invention aims to provide a detection method of salbutamol sulfate solution related substances for inhalation, which can better control the quality of the salbutamol sulfate solution for inhalation.
At present, the quality detection method of salbutamol sulfate solution for inhalation is less, but the method has the problems of incomplete controlled impurity types and the like.
The impurity J in the invention is salbutamol, which is a known impurity in salbutamol sulfate solution for inhalation. For salbutamol sulfate solution for inhalation, China has import registration standard JX20160145 with strong credibility and authority for the drug, and detection methods for analyzing related substances in the salbutamol sulfate solution for inhalation are recorded in the standard.
Surprisingly, however, the inventors have found that by repeated experiments, it is indeed impossible to completely separate the major peak from impurity J in the solution of albuterol sulphate by inhalation using the method described in the imported registered standard JX 20160145.
In the invention, the inventor develops a new method, which can effectively separate the impurity J from the main drug, and further carry out good quality control on the impurity J.
The invention provides a method for detecting related substances of salbutamol sulfate, which adopts high performance liquid chromatography to qualitatively or/and quantitatively detect related impurities of salbutamol sulfate, and the detection conditions of the liquid chromatography comprise:
a chromatographic column: octane silane bonding silica gel column or equivalent chromatographic column;
mobile phase: mobile phase A and mobile phase B;
wherein, the mobile phase A is phosphate buffer solution; the mobile phase B is a mixed solution of acetonitrile and/or methanol; the mobile phase was subjected to the following gradient elution procedure:
| time (min) | Mobile phase a (vol.%) | Mobile phase B (vol.%) |
| 0 | 90～99 | 1～10 |
| 5～20 | 90～99 | 1～10 |
| 20～40 | 60～80 | 20～40 |
。
In addition, the inventors have found that 5-hydroxysalbutamol as an impurity is contained in a salbutamol sulfate solution for inhalation in the study of the above impurity J. However, surprisingly, the inventors also tested salbutamol sulphate drug substance before the impurity was found in the solution for inhalation, and no 5-hydroxysalbutamol was found in the drug substance, as shown in figure 6. It is seen that the impurities present in the drug substance and the pharmaceutical preparation are not completely the same, and the type of impurity in one cannot be predicted from the impurity in the other. There have been no reports on the inclusion of 5-hydroxysalbutamol as an impurity in salbutamol sulfate solution for inhalation.
Further, the mobile phase B is acetonitrile: the volume ratio of methanol is (20-80): (80-20) mixing the solution; the mobile phase was subjected to the following gradient elution procedure:
| time (min) | Mobile phase a (vol.%) | Mobile phase B (vol.%) |
| 0 | 95～99 | 1～5 |
| 10～15 | 95～99 | 1～5 |
| 30～35 | 65～75 | 25～35 |
；
Further, mobile phase B was acetonitrile: the volume ratio of methanol is (40-65): (60-35) of a mixed solution;
further, the mobile phase was subjected to the following gradient elution procedure:
| time (min) | Mobile phase a (vol.%) | Mobile phase B (vol.%) |
| 0 | 97 | 3 |
| 10～15 | 97 | 3 |
| 30～35 | 70 | 30 |
。
In the gradient elution procedure of the mobile phase, the time is limited to 35min, and does not mean that the gradient elution procedure only comprises 0-35 min, the limitation of the gradient elution procedure is considered as an open limitation, and the gradient elution procedure can also comprise other elution procedures after 35 min.
The impurities are introduced in the technological processes of synthesis and the like, and comprise reactants, intermediates, byproducts, reagents, catalysts and the like.
Further, the impurities comprise at least the impurity J and/or 5-hydroxysalbutamol.
The phosphate buffer mainly comprises phosphate buffer prepared by using phosphate or/and hydrogen phosphate or/and dihydrogen phosphate or/and acid or/and alkali or/and other salts.
Further, the phosphate buffer solution contains hydrogen phosphate ions, dihydrogen phosphate ions, phosphate ions and alkali metal ions; further, the alkali metal ions are selected from one or two of potassium ions and sodium ions. For example, a solution containing hydrogen phosphate ions, dihydrogen phosphate ions, and potassium ions, a solution containing hydrogen phosphate ions, dihydrogen phosphate ions, and sodium ions, or a solution containing hydrogen phosphate ions, dihydrogen phosphate ions, potassium ions, and sodium ions may be mentioned.
In a specific embodiment of the present invention, the phosphate buffer is a phosphate-phosphate buffer; further, the phosphate buffer solution is a sodium dihydrogen phosphate solution with the concentration of 0.025 +/-0.002 mmol/L, and also comprises triethylamine, and the pH value of the phosphate buffer solution is adjusted to 2.0-4.0 by using phosphoric acid to obtain the phosphate buffer solution; wherein the volume concentration of the triethylamine is 0.03-0.07%.
Further, the phosphate buffer was adjusted to pH 3 with phosphoric acid and the triethylamine volume concentration was 0.05%.
In a particular embodiment of the invention, the organic phase is selected from acetonitrile: the volume ratio of methanol is 40: 60 of a mixed solution; the mobile phase was eluted after 35min using the following gradient elution procedure:
| time (min) | Mobile phase a (vol.%) | Mobile phase B (vol.%) |
| 37 | 70 | 30 |
| 37.01 | 10 | 90 |
。
In a preferred embodiment of the invention, the organic phase is selected from acetonitrile: the volume ratio of methanol is 40: 60 of a mixed solution; the mobile phase was subjected to the following gradient elution procedure:
| time (min) | Mobile phase a (vol.%) | Mobile phase B (vol.%) |
| 0 | 97 | 3 |
| 15 | 97 | 3 |
| 35 | 70 | 30 |
| 37 | 70 | 30 |
| 37.01 | 10 | 90 |
。
Through the gradient elution procedure, the impurity J, the 5-hydroxyl salbutamol and the main peak can be well separated, and the peak shape is good.
Further, the liquid chromatography detection conditions further comprise one or more of the following i to iv:
i specification of chromatographic column: 4.6 is multiplied by 250mm, 3-5 μm;
ii column temperature: 28-32 ℃;
iii flow rate: 0.9-1.1 ml/min;
iv detection wavelength: 273. + -. 2 nm.
Further, the liquid chromatography detection conditions further comprise one or more of the following i to iv:
i specification of chromatographic column: 4.6X 250mm, 5 μm;
ii column temperature: 30 ℃;
iii flow rate: 1.0 ml/min;
iv detection wavelength: 273 nm.
The chromatographic columns used in the embodiments of the present invention are commercially available as Hypersil BDS C8 and COSMOSIL C8-MS, and are not limited to the above commercial products as long as the chromatographic columns satisfying the above description can be used in the detection method of the present invention.
Further, the detection method further comprises the following steps of preparing a test solution or/and a reference solution: and (3) dissolving the sample by using a diluent and diluting the sample to a specified concentration, wherein the diluent is a mobile phase A.
Further, the detection method further comprises the following steps:
(1) injecting a control solution for detection;
(2) and (5) injecting a sample solution for detection.
The detection method can analyze and calculate the detection result by using methods such as an area normalization method, a self-comparison method, an internal standard method, an external standard method and the like.
In a specific embodiment of the present invention, the impurity content is calculated using an area normalization method.
Furthermore, the sample amount is 20 to 100. mu.l, preferably 50. mu.l.
The invention also provides a salbutamol sulfate solution for inhalation, which comprises salbutamol sulfate, salbutamol ketone and 5-hydroxy salbutamol, wherein the content of the salbutamol ketone is not more than 0.3 percent, and the content of the 5-hydroxy salbutamol is not more than 0.3 percent.
The invention has the beneficial effects that:
(1) the detection method of the invention is adopted to carry out quality control on the salbutamol sulfate solution for inhalation, can detect the 5-hydroxy salbutamol which is not detected before, and can better carry out quality control on the salbutamol sulfate solution for inhalation.
(2) The detection method can simultaneously control the quality of the impurity J and the 5-hydroxyl salbutamol of the salbutamol sulfate, can realize effective separation between the impurities and a main peak, and has better peak shape than the prior art, thus being more suitable for the quality control of the salbutamol sulfate solution for inhalation.
Drawings
FIG. 1 is a detection spectrum of condition 1;
FIG. 2 is a detection spectrum of condition 2;
FIG. 3 is a detection spectrum of condition 3;
FIG. 4 is a detection spectrum of condition 4;
FIG. 5 is a detection spectrum of condition 5;
FIG. 6 is a spectrum of salbutamol sulfate drug substance.
Detailed description of the invention
The detection method of the present invention is further described below by way of specific embodiments and experiments.
Example 1
Solution preparation:
diluent agent: mobile phase a.
Test solution: taking 1 piece of the product, precisely measuring 1ml, placing into a 10ml measuring flask, diluting with diluent to scale, and shaking.
System applicability solution: accurately weighing appropriate amount of 5-hydroxy salbutamol, impurity J and salbutamol sulfate reference substance, dissolving with diluent, and diluting to obtain mixed solution containing salbutamol 0.2mg and impurity (including 5-hydroxy salbutamol) 0.4 μ g each per 1ml, and using as system applicability solution.
(1) Condition 1: chromatographic method for performing import registration standard JX20160145
The method is confirmed, the chromatographic conditions are shown in Table 1, and the detection results are shown in FIG. 1.
TABLE 1 confirmation of chromatographic conditions by method JX20160145
The result of the confirmation of the chromatographic method of JX20160145 shows that under the chromatographic condition, the impurity J and the salbutamol sulfate peak partially coincide and cannot be separated, so that the method is not suitable for detecting substances related to the salbutamol sulfate solution for inhalation, and a method for detecting substances related to the salbutamol sulfate solution for inhalation needs to be further developed.
(2) Condition 2
The gradient was further optimized on the basis of condition 1 in an attempt to obtain good separation and peak shape. The chromatographic conditions are shown in Table 2, and the results are shown in FIG. 2.
TABLE 2 chromatographic conditions 2
The result shows that the impurity J and the main peak achieve baseline separation, and the 5-hydroxyl salbutamol can be well separated from the impurity J and the main peak.
(3) Condition 3
The composition of mobile phase B was further optimized on the basis of condition 2, the chromatographic conditions are shown in table 3, and the results are shown in fig. 3.
TABLE 3 chromatographic conditions 3
The results show that under the chromatographic conditions, baseline separation is achieved among 5-hydroxysalbutamol, impurity J and the main peak.
(4) Condition 4
The composition of mobile phase B was further optimized on the basis of condition 3, the chromatographic conditions are shown in table 4, and the results are shown in fig. 4.
TABLE 4 chromatographic conditions 4
The result shows that under the chromatographic condition, the 5-hydroxyl salbutamol, the impurity J and the main peak all meet the requirement of baseline separation.
(5) Condition 5
The chromatographic column is replaced on the basis of the condition 4, the equilibrium time of the chromatographic column at the tail end of the gradient is prolonged, the chromatographic conditions are shown in a table 5, and the result is shown in a table 5.
TABLE 5 chromatographic conditions 5
The result shows that under the chromatographic condition, the 5-hydroxy salbutamol, the impurity J, the main peak and other impurities can be well separated from the impurities and from the main peak, and a good peak shape can be obtained, so that the detection requirement of related substances of the salbutamol sulfate solution for inhalation can be met. Meanwhile, the content of 5-hydroxysalbutamol was measured to be 0.14%, and the content of impurity J was measured to be 0.11%.
The content of impurities can be calculated by the following formula:
in the formula: a. thesam-impurity peak area in the test sample solution;
Am-peak area of salbutamol in the test solution.
Example 2 detection of drug substances
The chromatographic conditions in table 6 were used:
TABLE 6
Fig. 6 is a detection spectrogram of the raw material drug, and it can be seen that the raw material drug has high purity and hardly contains any impurities.
Methodology validation report:
TABLE 7 verification project and results Profile
The analysis method verifies that the method has good specificity, the blank auxiliary materials do not interfere impurity detection, each impurity is well separated from the main peak, the detection limit and the quantitative limit of each impurity meet the determination requirement, and the linearity of each impurity is good; the method is proved to have better durability by fine adjustment of chromatographic conditions.
In conclusion, the detection method is superior to the existing chromatographic conditions in the import registration standard, can be used for qualitatively/quantitatively controlling the impurity J and the 5-hydroxysalbutamol in the salbutamol sulfate, can realize effective separation among the 5-hydroxysalbutamol, the impurity J and the main peak, can obtain good peak shape and separation, and is efficient and rapid.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications of equivalent structures and equivalent processes performed by the present specification and drawings, or directly or indirectly applied to other related technical fields, are included in the scope of the present invention.
Claims (10)
1. A detection method of salbutamol sulfate related substances is characterized in that high performance liquid chromatography is adopted for qualitative or/and quantitative detection of salbutamol sulfate related impurities, and the detection conditions of the liquid chromatography comprise:
a chromatographic column: octane silane bonding silica gel column or equivalent chromatographic column;
mobile phase: mobile phase A and mobile phase B;
wherein, the mobile phase A is phosphate buffer solution; the mobile phase B is a mixed solution of acetonitrile and/or methanol; the mobile phase was subjected to the following gradient elution procedure:
。
2. The detection method according to claim 1, wherein the mobile phase B is acetonitrile: the volume ratio of methanol is (20-80): (80-20) mixing the solution; the mobile phase was subjected to the following gradient elution procedure:
；
Further, mobile phase B was acetonitrile: the volume ratio of methanol is (40-65): (60-35) of a mixed solution;
further, the mobile phase was subjected to the following gradient elution procedure:
。
3. The detection method according to claim 1, wherein the impurity at least includes impurity J and/or 5-hydroxysalbutamol.
4. The method according to claim 1, wherein the phosphate buffer solution contains hydrogen phosphate ions, dihydrogen phosphate ions, and alkali metal ions; further, the alkali metal ions are selected from one or two of potassium ions and sodium ions.
5. The method of detecting according to claim 4, wherein the phosphate buffer is a phosphate-phosphate buffer; further, the phosphate buffer solution is a sodium dihydrogen phosphate solution with the concentration of 0.025 +/-0.002 mmol/L, and also comprises triethylamine, and the pH value of the phosphate buffer solution is adjusted to 2.0-4.0 by using phosphoric acid to obtain the phosphate buffer solution; wherein the volume concentration of the triethylamine is 0.03-0.07%.
6. The detection method according to claim 5, wherein the phosphate buffer is adjusted to pH 3 with phosphoric acid and the triethylamine is present at a concentration of 0.05% by volume.
7. The detection method according to claim 6, wherein the organic phase is selected from the group consisting of acetonitrile: the volume ratio of methanol is 40: 60 of a mixed solution; the mobile phase was eluted after 35min using the following gradient elution procedure:
。
8. The detection method according to any one of claims 1 to 7, wherein the liquid chromatography detection conditions further include one or more of the following i to iv:
i specification of chromatographic column: 4.6 is multiplied by 250mm, 3-5 μm;
ii column temperature: 28-32 ℃;
iii flow rate: 0.8-1.2 ml/min;
iv detection wavelength: 273. + -. 2 nm.
Further, the liquid chromatography detection conditions further comprise one or more of the following i to iv:
i specification of chromatographic column: 4.6X 250mm, 5 μm;
ii column temperature: 30 ℃;
iii flow rate: 1.0 ml/min;
iv detection wavelength: 273 nm;
furthermore, the amount of sample is 20 to 100. mu.l, preferably 50. mu.l.
9. The detection method according to any one of claims 1 to 7, further comprising preparing a test solution or/and a control solution: and (3) dissolving the sample by using a diluent and diluting the sample to a specified concentration, wherein the diluent is a mobile phase A.
10. An albuterol sulfate solution for inhalation, comprising albuterol sulfate, salbutamol ketone and 5-hydroxysalbutamol, wherein the content of the albuterol ketone is not more than 0.3%, and the content of the 5-hydroxysalbutamol is not more than 0.3%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910950434.0A CN110632205A (en) | 2019-10-08 | 2019-10-08 | Method for detecting salbutamol sulfate solution related substances for inhalation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910950434.0A CN110632205A (en) | 2019-10-08 | 2019-10-08 | Method for detecting salbutamol sulfate solution related substances for inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110632205A true CN110632205A (en) | 2019-12-31 |
Family
ID=68975757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910950434.0A Pending CN110632205A (en) | 2019-10-08 | 2019-10-08 | Method for detecting salbutamol sulfate solution related substances for inhalation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110632205A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114034782A (en) * | 2021-09-23 | 2022-02-11 | 北京四环科宝制药有限公司 | Method for detecting salbutamol sulfate related substances |
| CN115248273A (en) * | 2022-06-21 | 2022-10-28 | 浙江福瑞喜药业有限公司 | Method for detecting related substances of salbutamol sulfate solution for inhalation |
| CN115463117A (en) * | 2022-09-14 | 2022-12-13 | 四川普锐特药业有限公司 | Budesonide salbutamol compound atomized inhalation suspension with high delivery efficiency and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100998578A (en) * | 2007-01-10 | 2007-07-18 | 上海现代药物制剂工程研究中心有限公司 | Salbutamol water aerosol used for treating asthma |
| CN108181463A (en) * | 2017-12-11 | 2018-06-19 | 华南农业大学 | A kind of beta-2-agonists haptens and artificial antibody and its preparation method and application |
| CN108627597A (en) * | 2018-05-25 | 2018-10-09 | 成都倍特药业有限公司 | A kind of detection method of the salbutamol sulfate in relation to substance |
| CN109896968A (en) * | 2019-03-28 | 2019-06-18 | 上海葆隆生物科技有限公司 | Salbutamol sulfate impurity and preparation method thereof |
-
2019
- 2019-10-08 CN CN201910950434.0A patent/CN110632205A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100998578A (en) * | 2007-01-10 | 2007-07-18 | 上海现代药物制剂工程研究中心有限公司 | Salbutamol water aerosol used for treating asthma |
| CN108181463A (en) * | 2017-12-11 | 2018-06-19 | 华南农业大学 | A kind of beta-2-agonists haptens and artificial antibody and its preparation method and application |
| CN108627597A (en) * | 2018-05-25 | 2018-10-09 | 成都倍特药业有限公司 | A kind of detection method of the salbutamol sulfate in relation to substance |
| CN109896968A (en) * | 2019-03-28 | 2019-06-18 | 上海葆隆生物科技有限公司 | Salbutamol sulfate impurity and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| SATYAJIT V. ERRAM ET AL.: "Determination of albuterol sulfate and its related substances in albuterol sulfate inhalation solution, 0.5% by RP-HPLC", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 * |
| 国家药典委员会: "《中华人民共和国药典 2010年版》", 31 August 2012, 中国医药科技出版社 * |
| 曾丹: "左旋沙丁胺醇有关物质检查与生物样品测定", 《中国优秀博硕士学位论文全文数据库(硕士) 医药卫生科技辑》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114034782A (en) * | 2021-09-23 | 2022-02-11 | 北京四环科宝制药有限公司 | Method for detecting salbutamol sulfate related substances |
| CN114034782B (en) * | 2021-09-23 | 2024-01-30 | 安徽四环科宝制药有限公司 | Detection method of salbutamol sulfate related substances |
| CN115248273A (en) * | 2022-06-21 | 2022-10-28 | 浙江福瑞喜药业有限公司 | Method for detecting related substances of salbutamol sulfate solution for inhalation |
| CN115248273B (en) * | 2022-06-21 | 2023-10-13 | 浙江福瑞喜药业有限公司 | Method for detecting related substances of salbutamol sulfate solution for inhalation |
| CN115463117A (en) * | 2022-09-14 | 2022-12-13 | 四川普锐特药业有限公司 | Budesonide salbutamol compound atomized inhalation suspension with high delivery efficiency and preparation method thereof |
| CN115463117B (en) * | 2022-09-14 | 2024-06-04 | 四川普锐特药业有限公司 | A budesonide-salbutamol compound atomized inhalation suspension with high delivery efficiency and a preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108627597B (en) | Detection method of salbutamol sulfate related substances | |
| CN110632205A (en) | Method for detecting salbutamol sulfate solution related substances for inhalation | |
| CN108152418B (en) | HPLC detection method for ketorolac tromethamine or/and impurities in preparation of ketorolac tromethamine | |
| CN107870217B (en) | Detection method of eltrombopag intermediate I related substances | |
| US20240044851A1 (en) | Method for detecting content of active ingredients of compound sophorae flavescentis radix injection and fingerprint spectrum thereof | |
| CN111239299B (en) | Method for separating and measuring palbociclib and impurities thereof | |
| CN108872431B (en) | Method for detecting 4- (1- (2, 5-dimethylphenyl) ethyl) -1H-imidazole or/and hydrochloride thereof | |
| CN113049687A (en) | Method for detecting related substances of ambroxol hydrochloride raw material and injection | |
| CN113281423A (en) | Glimepiride impurity and analysis method thereof in Glimepiride bulk drug and preparation | |
| CN114755320B (en) | Detection method of 3-amino-6-methoxypyridazine related substances | |
| CN117517528A (en) | Detection method of related substances in intermediate of ponatinib | |
| CN111579653B (en) | Method for detecting related substances of fluconazole | |
| CN119310217B (en) | A method for detecting related substances of piperidine-4-carboxamide | |
| CN114062567B (en) | Separation and detection method of (1R, 2S) -2- (3, 4-difluorophenyl) cyclopropylamine hydrochloride and related substances thereof | |
| CN115656356B (en) | Determination of 4-hydroxy-7-phenoxyisoquinoline-3-carboxylic acid methyl ester and its related substances | |
| CN115791999B (en) | Detection method of impurity C in peramivir injection | |
| CN119355180A (en) | A method for detecting related substances in landiolol hydrochloride for injection | |
| CN119846089A (en) | Detection method of related substances of ibruting intermediate I | |
| CN107764905B (en) | Detection method of quinazoline-7-ether compound and related substances thereof | |
| CN119224180A (en) | A method for simultaneously detecting multiple impurities in revenacin solution for inhalation | |
| CN119846113A (en) | UPLC analysis method for levalbuterol hydrochloride inhalation solution | |
| CN120334383A (en) | Method for separating refenacin and its impurities by high performance liquid chromatography | |
| CN114527224A (en) | Dihydroxypropyltheophylline bulk drug and detection method of related substances in preparation thereof | |
| CN116046948A (en) | A method for analyzing related substances of compound preparation buprosrenin tablets | |
| CN117571856A (en) | An analysis method for nicorandil related substances for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: No. 15 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610000 Applicant after: Sichuan Pu et Pharmaceutical Co.,Ltd. Address before: No. 15 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610000 Applicant before: SICHUAN PURUITE MEDICAL TECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191231 |
|
| RJ01 | Rejection of invention patent application after publication |